----

| ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---------|--------------------------------------------------------------------------------------|
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---------|------------------------------------------------------------------------------------------|
| Delaware                                                       |   | 86-2494888                           |
|----------------------------------------------------------------|--------|--------------------------------------|
| (State or other jurisdiction of incorporation or organization) |   | (I.R.S. Employer Identification No.) |
|                                                           |   |                                 |
| 2655 Northwinds ParkwayAlpharetta, GA                          |   | 30009(Zip Code)                      |
| (Address of principal executive offices)                       |   |                                 |
| Title of Each Class                                                                                                      |  Trading Symbol | Name of Each Exchange on Which Registered |
|--------------------------------------------------------------------------------------------------------------------------|----------------------|-------------------------------------------|
| Units, each consisting of one share of Class A Common Stock and one-half of one redeemable warrant                       | RJAC.U               | The New York Stock Exchange               |
|                                                                                                                     |                 |                                      |
| Class A Common Stock, par value $0.0001 per share                                                                        | RJAC                 | The New York Stock Exchange               |
|                                                                                                                     |                 |                                      |
| Redeemable warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 | RJAC.WS              | The New York Stock Exchange               |

----

----

| Large accelerated filer ☐ | Accelerated filer ☐ | Non-accelerated filer ☒ | Smaller reporting company ☒ |
|---------------------------------|---------------------------|-------------------------------|-----------------------------------|
|                            |                      |                          |                              |
|                            |                      |                          | Emerging growth company ☒   |

----

|     |                                                                                                               | Page   |
|----------|--------------------------------------------------------------------------------------------------------------------|--------|
|     | PART I                                                                                                             |   |
| Item 1:  | Business                                                                                                           | 3      |
| Item 1A: | Risk Factors                                                                                                       | 13     |
| Item 1B  | Unresolved Staff Comments                                                                                          | 46     |
| Item 2:  | Properties                                                                                                         | 46     |
| Item 3:  | Legal Proceedings                                                                                                  | 46     |
| Item 4:  | Mine Safety Disclosures                                                                                            | 46     |
|     |                                                                                                               |   |
|     | PART II                                                                                                            |   |
| Item 5:  | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 47     |
| Item 6:  | [Reserved]                                                                                                         | 48     |
| Item 7:  | Management’s Discussion and Analysis of Financial Condition and Results of Operations                        | 49     |
| Item 7A: | Quantitative and Qualitative Disclosures About Market Risk                                                         | 53     |
| Item 8:  | Financial Statements and Supplementary Data                                                                        | 53     |
| Item 9:  | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure                               | 54     |
| Item 9A: | Controls and Procedures                                                                                            | 54     |
| Item 9B: | Other Information                                                                                                  | 54     |
| Item 9C. | Disclosure Regarding Foreign Jurisdictions that Prevent Inspection                                                 | 54     |
|     |                                                                                                               |   |
|     | PART III                                                                                                           |   |
| Item 10: | Directors, Executive Officers and Corporate Governance                                                             | 55     |
| Item 11: | Executive Compensation                                                                                             | 63     |
| Item 12: | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters                     | 63     |
| Item 13: | Certain Relationships and Related Transactions, and Director Independence                                          | 66     |
| Item 14: | Principal Accountant Fees and Services                                                                             | 69     |
|     |                                                                                                               |   |
|     | PART IV                                                                                                            |   |
| Item 15: | Exhibits and Financial Statement Schedules                                                                         | 70     |
| Item 16: | Form 10‐K Summary                                                                                            | 70     |

----

Table of Contents

|  | • | our ability to select an appropriate target business or businesses; |
|--|---------|---------------------------------------------------------------------|
|  | • | our ability to complete our initial business combination; |
|--|---------|-----------------------------------------------------------|
|  | • | our expectations around the performance of a prospective target business or businesses; |
|--|---------|-----------------------------------------------------------------------------------------|
|  | • | our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination; |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | our directors and officers allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | our potential ability to obtain additional financing to complete our initial business combination; |
|--|---------|----------------------------------------------------------------------------------------------------|
|  | • | our pool of prospective target businesses and our target industries; |
|--|---------|----------------------------------------------------------------------|
|  | • | our ability to consummate an initial business combination due to the uncertainty resulting from the COVID-19 pandemic; |
|--|---------|------------------------------------------------------------------------------------------------------------------------|
|  | • | the ability of our directors and officers to generate a number of potential business combination opportunities; |
|--|---------|-----------------------------------------------------------------------------------------------------------------|
|  | • | our public securities’ liquidity and trading; |
|--|---------|-----------------------------------------------------|
|  | • | the market for our securities; |
|--|---------|--------------------------------|
|  | • | the use of proceeds not held in the trust account or available to us from interest income on the trust account balance; |
|--|---------|-------------------------------------------------------------------------------------------------------------------------|
|  | • | the trust account not being subject to claims of third parties; |
|--|---------|-----------------------------------------------------------------|
|  | • | our financial performance; or |
|--|---------|-------------------------------|
|  | • | other risks and uncertainties, including those described in the ‘‘Risk Factors’’ section of this Annual Report. |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | • | We are a recently incorporated company with no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective. |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Our public stockholders may not be afforded an opportunity to vote on our proposed business combination, which means we may complete our initial business combination even though a majority of our public stockholders do not support such a              combination. |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | If we seek stockholder approval of our initial business combination, our sponsor, directors and officers have agreed to vote in favor of such initial business combination, regardless of how our public stockholders vote. |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Your only opportunity to affect the investment decision regarding a potential business combination will be limited to the exercise of your right to redeem your shares from us for cash, unless we seek stockholder approval of such business              combination. |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | The ability of our public stockholders to redeem their shares for cash may make our financial condition unattractive to potential business combination targets, which may make it difficult for us to enter into a business combination with a              target. |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | The requirement that we complete our initial business combination within the prescribed time frame may give potential target businesses leverage over us in negotiating a business combination and may limit the time we have in which to              conduct due diligence on potential business combination targets, in particular as we approach our dissolution deadline, which could undermine our ability to complete our initial business combination on terms that would produce value for our              stockholders. |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Our search for a business combination, and any target business with which we ultimately consummate a business combination, may be materially adversely affected by the COVID-19 outbreak and other events and the status of debt and equity              markets. |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | We may not be able to complete our initial business combination within the prescribed time frame, in which case we would cease all operations except for the purpose of winding up and we would redeem our public shares and liquidate, in              which case our public stockholders may receive only $10.15 per share, or less than such amount in certain circumstances, and our warrants will expire worthless. |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Unlike many other blank check companies, we may extend the time to complete a business combination by three months without a stockholder vote or your ability to redeem your shares. |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | If we seek stockholder approval of our initial business combination, our sponsor, directors, officers, advisors or any of their respective affiliates may elect to purchase shares or warrants from public stockholders, which may influence a              vote on a proposed business combination and reduce the public “float” of our securities. |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Because of our limited resources and the significant competition for business combination opportunities, it may be more difficult for us to complete our initial business combination. If we have not completed our initial business              combination within the required time period, our public stockholders may receive only approximately $10.15 per share, or less in certain circumstances, on our redemption of their shares, and our warrants will expire worthless. |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | • | We may have limited ability to assess the management of a prospective target business and, as a result, may effect our initial business combination with a target business whose management may not have the skills, qualifications or              abilities to manage a public company. |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | We may be able to complete only one business combination with the proceeds of our initial public offering and the sale of the Private Placement Warrants, which will cause us to be solely dependent on a single business which may have a              limited number of products or services. This lack of diversification may negatively impact the results of operations and financial condition of the post-combination business. |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | We are dependent upon our directors and officers and their departure could adversely affect our ability to operate. |
|--|---------|---------------------------------------------------------------------------------------------------------------------|
|  | • | Our key personnel may negotiate employment or consulting agreements with a target business in connection with a particular business combination. These agreements may provide for them to receive compensation following our initial business              combination and as a result, may cause them to have conflicts of interest in determining whether a particular business combination is the most advantageous. |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Our directors and officers will allocate their time to other businesses thereby causing conflicts of interest in their determination as to how much time to devote to our affairs. This conflict of interest could have a negative impact on              our ability to complete our initial business combination. |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Our directors, officers, security holders and their respective affiliates may have competitive pecuniary interests that conflict with our interests. |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | The ability of our public stockholders to exercise redemption rights with respect to a large number of our shares could increase the probability that our initial business combination would be unsuccessful and that you would have to wait              for liquidation in order to redeem your shares. |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | You will not have any rights or interests in funds from the trust account, except under certain limited circumstances. To liquidate your investment, therefore, you may be forced to sell your public shares and/or warrants, potentially at a              loss. |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | The New York Stock Exchange may delist our securities from trading on its exchange, which could limit investors’ ability to make transactions in our securities and subject us to additional trading restrictions. |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | You will not be entitled to protections normally afforded to investors of many other blank check companies. |
|--|---------|-------------------------------------------------------------------------------------------------------------|
|  | • | If we seek stockholder approval of our initial business combination and we do not conduct redemptions pursuant to the tender offer rules, and if you or a “group” of stockholders are deemed to hold in excess of 15% of the outstanding shares              of our Class A Common Stock, you will lose your ability to redeem all such shares in excess of 15% of the outstanding shares of our Class A Common Stock. |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | We have identified a material weakness in our internal control over financial reporting as of December 31, 2021. If we are unable to develop and maintain an effective system of internal control over financial reporting, we may not be able              to accurately report our financial results in a timely manner, which may adversely affect investor confidence in us and materially and adversely affect our business and operating results. |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| ITEM 1. | BUSINESS |
|---------|----------|

----

Table of Contents

----

Table of Contents

|  | • | Large and Growing Market Opportunity. We believe that the healthcare services industry represents a significant market opportunity. According to CMS, total U.S. healthcare              expenditures reached approximately $3.8 trillion in 2019, and CMS has estimated that total U.S. healthcare spending will constitute approximately 20% of projected U.S. gross domestic product in 2028. We believe the current trajectories of              healthcare spending will encourage the development of new technologies and present valuable opportunities for growth in the healthcare space. |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Shift from Volume-Based care to Value-Based Care. In traditional volume-based care, or fee-for-service, healthcare providers are              reimbursed for the number of services ordered. In these models, neither quality of care nor necessity of individual services (tests, procedures, etc.) are emphasized. The recent shift to performance-based care, or a more holistic approach to              treatment, is intended to enhance cost efficiency while holding providers accountable for the quality of services they offer through risk-sharing models. This change is expected to significantly alter the dynamics of the U.S. healthcare              system and to create opportunities for businesses to enter the healthcare space and make a difference in patient care. |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Accelerating Shift of Care to Lower Cost Settings. There has been a significant shift toward alternative sites and consumer convenience in recent years. We expect to continue to              see an increased volume mix to outpatient care, particularly in lower-cost sites outside of the hospital as consumers gravitate to retail-friendly models and lower out-of-pocket costs. |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Macro Trends. Total U.S. healthcare expenditures are projected to grow at an average annual rate of approximately 5.4% from 2019 through 2028, according to CMS. Explanatory              factors for this projected growth include an aging population, increasing prevalence of chronic diseases and improved access to healthcare products and services. This projected growth trajectory has put significant pressure on payors, which              suggests favorable trends for healthcare companies that can control costs while improving access and overall quality of healthcare. |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Increased Emphasis Due to COVID-19 Pandemic. The COVID-19 pandemic has amplified the attention paid to the U.S. healthcare system. Public and private entities are placing an              increasing emphasis on the resilience and stability of the system, in particular shortening supply chains, reducing reliance on offshore suppliers, and improving reliability and efficiency. We expect this dynamic to favor domestic companies              that can reduce cost and improve quality of and access to care. |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Technological Advances and Spread of Social Media. Recent years have seen great advances in electronic healthcare services (e.g., electronic medical records, telehealth, awareness              of mental health on social media, etc.). Combined with shifts in the methods of healthcare delivery in the U.S. (e.g., value-based care), we believe that there are attractive opportunities for development of flagship products or services. |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Gaps in Access, Quality and Affordability of Healthcare. Despite healthcare reform designed to make health insurance accessible to a broader range of the U.S. population, we              believe that significant healthcare disparities have persisted and, in some cases, widened. Our management team is committed to closing these gaps and believes that it requires ongoing technological innovation, increasing attention towards              the social determinants of health, and continued cost containment in addition to public policy actions and fiscal support. These challenging dynamics are expected to continue to put pressure on healthcare services companies to act with speed,              creativity and resilience-and reward those that can do so-regardless of the regulatory or political environment. |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Risk-Based Providers and Services. The increasing cost of care has prompted a transition to value-based care models that are designed to reduce unnecessary healthcare spending.              CMS estimates that total U.S. healthcare spending in 2019 was approximately $3.8 trillion. A report published by JAMA Network in 2019 estimated that approximately one-quarter of all U.S. healthcare spending was due to healthcare waste,              including unnecessary services, excessive administrative costs and fraud. We believe that this creates a market opportunity for provider organizations that engage in capitated models designed to share in the risk associated with the              healthcare costs of their underlying patient population. There has also been an increased emphasis on provider training and continuing education. |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | • | Alternate Site Healthcare Provider and Services. Rising healthcare expenditures are prompting industry players to transition to less expensive care settings. Hospitals, clinics              and other traditional care sites are seeking to reduce expenses and launch value-based care initiatives, including a shift to outpatient and retail care sites, such as urgent care clinics and ambulatory surgical centers. Enhanced by digital              health innovations and technologies, we expect such alternate site healthcare providers to drive the integration of the industry and to reduce the overall cost of healthcare. |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Home Care and Hospices. The elderly population of the U.S. continues to grow, resulting in an ongoing need for long-term care. We believe that many elderly patients now prefer the              home care model to traditional hospitals. In addition, technology advances are expected to improve care delivery, enabling better patient care in a home environment and saving costly hospital spending. Despite the sector being very              fragmented, home care is projected to be one of the two fastest growing sectors of the U.S. healthcare economy, and the fifth fastest growing industry in the U.S. economy generally, based on projected net growth in employment from 2019              through 2029, according to 2020 data appearing on the U.S. Bureau of Labor Statistics’ “The Economics Daily” website. |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Behavioral Health. According to a 2018 survey by the Substance Abuse and Mental Health Services Administration, an agency within the U.S. Department of Health and Human Services,              approximately one out of five adults in the U.S. experiences a mental health disorder, yet only approximately 45% of those adults receive treatment. We believe that the rise of telehealth in the last few years and the general industry shift              to alternate health sites have increased patients’ access to and the overall usage of behavioral health treatments. |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | operating companies in the public and private markets, defining corporate strategy, and identifying, mentoring and recruiting leading talent, and identifying and executing on operational improvements that drive value; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | growing companies, both organically and through strategic transactions, expanding product portfolios and broadening geographic footprints; |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | building strong sales networks to drive organic growth across market segments, targeting a wide range of payor and referral sources, with a focus on compliance and customer service across all parties in the care delivery and reimbursement              chain; |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | strategically investing in leading private and public healthcare and other companies to help accelerate growth and maturation; |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------|
|  | • | sourcing, structuring, acquiring and selling businesses; |
|--|---------|----------------------------------------------------------|

----

Table of Contents

|  | • | accessing public and private capital markets to optimize capital structure, including financing businesses and helping companies transition ownership structures; and |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | fostering relationships with sellers, capital providers and experienced target management teams. |
|--|---------|--------------------------------------------------------------------------------------------------|
|  | • | Industry Attractiveness. Macro industry dynamics, including the healthcare regulatory and reimbursement situation, must be favorable on a go-forward basis. Healthcare companies              can utilize the extensive networks and insights that members of our management team have built in the sector to drive meaningful operational improvements and efficiency gains or to enhance their strategic position by using technology              solutions to differentiate its offering. |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Strong Management Team. We will seek to acquire businesses or companies with seasoned and strong management teams. Our team brings a breadth of knowledge and plans to focus on              assets that represent the same values, proven track records, and work ethic. |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Growth Potential. We will seek to target propositions with significant growth potential with the addition of our management team and resources. |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Value Proposition. We will seek businesses or companies with clear value proposition, including how success will be measured and demonstrated to investors and that we believe are              positioned to provide attractive risk-adjusted equity returns for our stockholders. |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Benefit from Access to Public Investors. We will seek to target companies that are ready to become public, with strong management, corporate governance and reporting policies in              place, and which we believe will likely be well received by public investors and are expected to have good access to the public capital markets. |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|  | • | conduct the redemptions pursuant to Rule 13e-4 and Regulation 14E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which regulate issuer tender offers; and |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about the initial business combination and the              redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies. |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | conduct the redemptions in conjunction with a proxy solicitation pursuant to Regulation 14A of the Exchange Act, which regulates the solicitation of proxies, and not pursuant to the tender offer rules; and |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | file proxy materials with the SEC. |
|--|---------|------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

| ITEM 1A. | RISK FACTORS. |
|----------|---------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | • | restrictions on the nature of our investments; and |
|--|---------|----------------------------------------------------|
|  | • | restrictions on the issuance of securities; each of which may make it difficult for us to complete our initial business combination. |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------|
|  | • | registration as an investment company with the SEC; |
|--|---------|-----------------------------------------------------|
|  | • | adoption of a specific form of corporate structure; |
|--|---------|-----------------------------------------------------|
|  | • | reporting, record keeping, voting, proxy and disclosure requirements and other rules and regulations that we are currently not subject to. |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | • | solely dependent upon the performance of a single business, property or asset; or |
|--|---------|-----------------------------------------------------------------------------------|
|  | • | dependent upon the development or market acceptance of a single or limited number of products, processes or services. |
|--|---------|-----------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|  | • | costs and difficulties inherent in managing cross-border business operations and complying with commercial and legal requirements of overseas markets; |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | rules and regulations regarding currency redemption; |
|--|---------|------------------------------------------------------|
|  | • | complex corporate withholding taxes on individuals; |
|--|---------|-----------------------------------------------------|
|  | • | laws governing the manner in which future business combinations may be effected; |
|--|---------|----------------------------------------------------------------------------------|

----

Table of Contents

|  | • | tariffs and trade barriers; |
|--|---------|-----------------------------|
|  | • | regulations related to customs and import/export matters; |
|--|---------|-----------------------------------------------------------|
|  | • | longer payment cycles; |
|--|---------|------------------------|
|  | • | changes in local regulations as part of a response to the COVID-19 outbreak; |
|--|---------|------------------------------------------------------------------------------|
|  | • | tax consequences, such as tax law changes, including termination or reduction of tax and other incentives that the applicable government provides to domestic companies, and variations in tax laws as compared to              the United States; |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | currency fluctuations and exchange controls, including devaluations and other exchange rate movements; |
|--|---------|--------------------------------------------------------------------------------------------------------|
|  | • | rates of inflation, price instability and interest rate fluctuations; |
|--|---------|-----------------------------------------------------------------------|
|  | • | liquidity of foreign capital and lending markets; |
|--|---------|---------------------------------------------------|
|  | • | challenges in collecting accounts receivable; |
|--|---------|-----------------------------------------------|
|  | • | cultural and language differences; |
|--|---------|------------------------------------|
|  | • | employment regulations; |
|--|---------|-------------------------|
|  | • | energy shortages; |
|--|---------|-------------------|
|  | • | crime, strikes, riots, civil disturbances, terrorist attacks, natural disasters, wars and other forms of social instability; |
|--|---------|------------------------------------------------------------------------------------------------------------------------------|
|  | • | deterioration of political relations with the United States; |
|--|---------|--------------------------------------------------------------|
|  | • | obligatory military service by personnel; and |
|--|---------|-----------------------------------------------|
|  | • | government appropriation of assets |
|--|---------|------------------------------------|

----

Table of Contents

|  | • | Competition could adversely affect our results and operations. |
|--|---------|----------------------------------------------------------------|
|  | • | Our inability to comply with governmental regulations affecting the healthcare industry could negatively affect our operations. |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------|
|  | • | We may be unable to license or enforce intellectual property rights on which our business may depend. |
|--|---------|-------------------------------------------------------------------------------------------------------|
|  | • | The success of our planned business following consummation of our initial business combination may depend on maintaining a secure business and information technology infrastructure. |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | If we are required to obtain governmental approval of our products, the production of our products could be delayed and we could be required to engage in a lengthy and expensive approval process that may not              ultimately be successful. |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Continuing government and private efforts to contain healthcare costs, including through the implementation of legal and regulatory changes, may adversely affect our results of operations and financial              condition following such business combination. |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Changes in the healthcare related wellness industry and markets for such products affecting our customers or retailing practices could negatively impact customer relationships and our results of operations and              financial condition. |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | The healthcare industry is susceptible to significant liability exposure. If liability claims are brought against us following a business combination, it could materially adversely affect our results of              operations and financial condition. |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Dependence of our operations upon third-party suppliers, manufacturers or contractors whose failure to perform adequately could disrupt our business. |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | The Affordable Care Act, possible changes to it or its repeal, and how it is implemented could negatively impact our business. |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------|
|  | • | A disruption in supply could adversely impact our business. |
|--|---------|-------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | (i) | we issue additional shares of Class A Common Stock or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination at a Newly Issued Price of less              than $9.20 per share of Class A Common Stock, |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | (ii) | the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination on the date of the              completion of our initial business combination (net of redemptions), and |
|--|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | (iii) | the Market Value of our Class A Common Stock is below $9.20 per share. |
|--|-------|------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | • | a limited availability of market quotations for our securities; |
|--|---------|-----------------------------------------------------------------|
|  | • | reduced liquidity for our securities; |
|--|---------|---------------------------------------|
|  | • | a determination that our Class A Common Stock is a “penny stock” which will require brokers trading in our Class A Common Stock to adhere to more stringent rules and possibly result in a reduced level of              trading activity in the secondary trading market for our securities; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | a limited amount of news and analyst coverage; and |
|--|---------|----------------------------------------------------|
|  | • | a decreased ability for us to issue additional securities or obtain additional financing in the future. |
|--|---------|---------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | • | may significantly dilute the equity interest of investors, which dilution would increase if the anti-dilution provisions in the shares of our Class B Common Stock resulted in the issuance of shares of our Class              A Common Stock on a greater than one-to-one basis upon conversion of the shares of our Class B Common Stock; |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | may subordinate the rights of holders of shares of common stock if shares of preferred stock are issued with rights senior to those afforded our shares of common stock; |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | could cause a change of control if a substantial number of our shares of common stock is issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could              result in the resignation or removal of our present directors and officers; |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | may have the effect of delaying or preventing a change of control of us by diluting the share ownership or voting rights of a person seeking to obtain control of us; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | may adversely affect prevailing market prices for our Units, shares of Class A Common Stock and/or warrants; and |
|--|---------|------------------------------------------------------------------------------------------------------------------|
|  | • | may not result in adjustment to the exercise price of our warrants. |
|--|---------|---------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|  | • | default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations; |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or              reserves without a waiver or renegotiation of that covenant; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | • | our immediate payment of all principal and accrued interest, if any, if the debt is payable on demand; |
|--|---------|--------------------------------------------------------------------------------------------------------|
|  | • | our inability to obtain necessary additional financing if the debt contains covenants restricting our ability to obtain such financing while the debt is outstanding; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | our inability to pay dividends, if any, on our common stock; |
|--|---------|--------------------------------------------------------------|
|  | • | using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our common stock if declared, expenses, capital expenditures,              acquisitions and other general corporate purposes; |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------|
|  | • | increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared              to our competitors who have less debt. |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ITEM 1B. | UNRESOLVED STAFF COMMENTS |
|----------|---------------------------|

| ITEM 2. | PROPERTIES |
|---------|------------|

| ITEM 3. | LEGAL PROCEEDINGS |
|---------|-------------------|
| ITEM 4. | MINE SAFETY DISCLOSURES |
|---------|-------------------------|

----

Table of Contents

| ITEM 5. | MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES |
|---------|--------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| ITEM 6. | [RESERVED] |
|---------|------------|

----

Table of Contents

| ITEM 7. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
|---------|---------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

| ITEM 7A. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET |
|----------|-------------------------------------------------------|
| ITEM 8. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA |
|---------|---------------------------------------------|

----

Table of Contents

| ITEM 9. | CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE |
|---------|--------------------------------------------------------------------------------------|
| ITEM 9A. | CONTROLS AND PROCEDURES |
|----------|-------------------------|
| ITEM 9B. | OTHER INFORMATION |
|----------|-------------------|
| ITEM 9C. | DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTION |
|----------|--------------------------------------------------------------------|

----

Table of Contents

| ITEM 10. | DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE |
|----------|--------------------------------------------------------|
| Name                              | Age | Position                           |
|-----------------------------------|-----|------------------------------------|
| John Ellis “Jeb” Bush | 69  | Chairman of the Board of Directors |
| David A. Perdue, Jr. (1)(2)(3)    | 72  | Director                           |
| Marilyn B. Tavenner (1)(2)(3)     | 70  | Director                           |
| Carlos A. Migoya (1)(2)(3)        | 71  | Director                           |

----

| (1) | Member of the audit committee. |
|-----|--------------------------------|
| (2) | Member of the compensation committee. |
|-----|---------------------------------------|
| (3) | Member of the nominating and corporate governance committee. |
|-----|--------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|  | • | assisting board oversight of (1) the integrity of our financial statements, (2) our compliance with legal and regulatory requirements, (3) our independent auditor’s qualifications and independence, and (4) the performance of our internal                audit function and independent auditors; |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | the appointment, compensation, retention, replacement, and oversight of the work of the independent auditors and the retention, direction, oversight of activities, and termination of the engagement of, any other independent registered                public accounting firm engaged by us; |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | pre-approving all services to be provided by the independent auditors or any other registered public accounting firm engaged by us; |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------|
|  | • | reviewing and discussing with the independent auditors relationships the auditors have with us in order to evaluate their continued independence; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | setting hiring policies for employees or former employees of the independent auditors; |
|--|---------|----------------------------------------------------------------------------------------|
|  | • | assuring the regular rotation of the audit partner in compliance with applicable laws and regulations; |
|--|---------|--------------------------------------------------------------------------------------------------------|
|  | • | evaluating, at least annually, a report from the independent auditors describing (1) the independent auditor’s internal quality-control procedures and (2) any material issues raised by the most recent internal quality-control review, or                peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities, within the preceding five years concerning any independent audits carried out by the firm and any steps taken to deal with such                issues; |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | meeting to review and discuss our annual audited financial statements and quarterly financial statements with management and the independent auditor, including reviewing our specific disclosures under “Management’s Discussion and                Analysis of Financial Condition and Results of Operations”; |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | reviewing and, if appropriate approving or ratifying any related party transaction and other significant conflicts of interest, in each case in accordance with our Code of Ethics (as defined below) and related person transaction policy;                and |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | reviewing with management, the independent auditors, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, and any employee complaints or published reports that raise material issues regarding our financial                statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities. |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | • | reviewing and approving the corporate goals and objectives relevant to the compensation of our Chief Executive Officer and other executive officers, evaluating their performance in light of such goals and objectives and determining and                approving, subject to such further action of our Board of Directors as the Board of Directors shall determine, the compensation of our Chief Executive Officer and other executive officers (including any awards under any equity-based                compensation or non-equity-based incentive compensation plan); |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | reviewing our executive compensation policies and plans; |
|--|---------|----------------------------------------------------------|
|  | • | administering our equity-based compensation plans; |
|--|---------|----------------------------------------------------|
|  | • | assisting management in complying with our proxy statement and annual report disclosure requirements; |
|--|---------|-------------------------------------------------------------------------------------------------------|
|  | • | approving any special perquisites, special cash payments and other special compensation and benefit arrangements for our officers and employees and any employment, compensation, benefit or severance agreement with any executive officer,                subject to such further action of our Board of Directors as the Board of Directors shall determine; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | producing a report on executive compensation to be included in our annual proxy statement; and |
|--|---------|------------------------------------------------------------------------------------------------|
|  | • | reviewing, evaluating and recommending changes, if appropriate, to the compensation for directors. |
|--|---------|----------------------------------------------------------------------------------------------------|
|  | • | identifying, screening and reviewing individuals qualified to serve as directors, consistent with criteria approved by the Board of Directors, and recommending to the Board of Directors candidates for nomination for election at the                annual stockholder meeting or to fill vacancies on the Board of Directors; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | developing and recommending to the Board of Directors and reviewing the effectiveness of our corporate governance policies; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------|
|  | • | coordinating and overseeing the annual self-evaluation of the Board of Directors, its committees, individual directors and management in the governance of the company; and |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | reviewing on a regular basis our overall corporate governance and recommending improvements as and when necessary. |
|--|---------|--------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| Name               |   | Age |   | Position                                        |
|--------------------|--------|-----|--------|-------------------------------------------------|
| Richard L. Jackson |   | 68  |   | President, Chief Executive Officer and Director |
| Douglas B. Kline   |   | 72  |   | Chief Financial Officer and Treasurer           |

----

Table of Contents

----

Table of Contents

|  | • | None of our directors or officers is required to commit his or her full time to our affairs and, accordingly, may have conflicts of interest in allocating his or her time among various business activities. |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | In the course of their other business activities, our directors and officers may become aware of investment and business opportunities that may be appropriate for presentation to us as well as the other                entities with which they are affiliated. Our management may have conflicts of interest in determining to which entity a particular business opportunity should be presented. |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Our initial stockholders, directors and officers have agreed to waive their redemption rights with respect to any founder shares and public shares held by them in connection with the consummation of our                initial business combination. Additionally, our initial stockholders have agreed to waive their redemption rights with respect to their founder shares if we fail to consummate our initial business combination by June 13, 2023 (or by                September 13, 2023 if the sponsor exercises its extension option) or during any Charter Extension Period. However, if our initial stockholders (or any of our directors, officers or affiliates) acquire public shares, they will be entitled to                liquidating distributions from the trust account with respect to such public shares if we fail to consummate our initial business combination within the prescribed time frame. If we do not complete our initial business combination within                such applicable time period, the proceeds of the sale of the private placement warrants held in the trust account will be used to fund the redemption of our public shares, and the private placement warrants will expire worthless. With                certain limited exceptions, the founder shares will not be transferable, assignable or salable by our initial stockholders until the earlier of: (1) one year after the completion of our initial business combination; and (2) subsequent to                our initial business combination (x) if the last reported sale price of shares of our Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, consolidations, reorganizations, recapitalizations                and other similar transactions) for any 20 trading days within any 30-trading day period commencing at least 150 days after our initial business combination or (y) the date on which we complete a liquidation, merger, capital stock exchange,                reorganization or other similar transaction that results in all of our public stockholders having the right to exchange their shares of common stock for cash, securities or other property. With certain limited exceptions, the private                placement warrants and the shares of common stock underlying such warrants, will not be transferable, assignable or salable by our sponsor until 30 days after the completion of our initial business combination. Since our sponsor and                directors and officers may directly or indirectly own shares of common stock and warrants, our directors and officers may have a conflict of interest in determining whether a particular target business is an appropriate business with which                to effectuate our initial business combination. |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Our directors and officers may negotiate employment or consulting agreements with a target business in connection with a particular business combination. These agreements may provide for them to receive                compensation following our initial business combination and as a result, may cause them to have conflicts of interest in determining whether to proceed with a particular business combination. |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Our directors and officers may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such directors and officers was included by a                target business as a condition to any agreement with respect to our initial business combination. |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|   | Individual          |   | Entity                                                                                                                                                                  |   | Entity’s Business                                                                 |   | Affiliation                                                                                        |
|--------|---------------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------------------------------------------|--------|----------------------------------------------------------------------------------------------------|
|   | Jeb Bush            |   | Jackson Healthcare (1)InnovAge Holding Corp.Get Heal, Inc.Finback Investment Partners LLCIHS Holding LimitedDock Square Capital LLC Jeb Bush & Associates, LLC |   | HealthcareHealthcareHealthcareInvestment FirmCommunicationsMerchant BankConsulting Firm |   | Advisory board memberDirectorDirectorChairmanDirectorChairmanChairman                              |
|   | Richard L. Jackson  |   | Jackson Healthcare (1) Jackson Investment Group (2)                                                                                                                |   | HealthcareInvestment Firm                                                               |   | Chief Executive Officer, Chairman of the Board Chief Executive Officer, Chairman of the Board |
|   | Marilyn B. Tavenner |   | InnovAge Holding Corp. Blue Cross Blue Shield of Arizona Select Medical Holdings Corporation                                                                  |   | HealthcareHealthcareHealthcare                                                          |   | DirectorDirectorDirector                                                                           |
|   | Carlos A. Migoya    |   | Jackson Health System (3)                                                                                                                                               |   | Healthcare                                                                              |   | President and CEO                                                                                  |

| (1) | Includes Jackson Healthcare and certain of its funds and other affiliated companies. |
|-----|--------------------------------------------------------------------------------------|

| (2) | Includes Jackson Investment Group and certain of its funds and other affiliated companies. |
|-----|--------------------------------------------------------------------------------------------|

| (3) | Not affiliated with Jackson Healthcare or Jackson Investment Group. |
|-----|---------------------------------------------------------------------|

----

Table of Contents

| ITEM 11. | EXECUTIVE COMPENSATION |
|----------|------------------------|
| ITEM 12. | SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS |
|----------|------------------------------------------------------------------------------------------------|
|  | • | each person known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock; |
|--|---------|---------------------------------------------------------------------------------------------------------------|
|  | • | each of our executive officers and directors; and |
|--|---------|---------------------------------------------------|
|  | • | all our executive officers and directors as a group. |
|--|---------|------------------------------------------------------|

----

Table of Contents

|    |  Class A Common Stock (1)                        |   Class B Common Stock (2) |                           |
|--------------|-------------------------------------------------------|--------------------------------------|-------------------------------------|
|         | Name and Address of Beneficial Owner                  |                                 | Number of Shares Beneficially Owned |   | Percentage of Shares Beneficially Owned |   | Number of Shares Beneficially Owned |   | Percentage of Shares Beneficially Owned |   | Percentage of Total Outstanding Common Stock (3) |
|         | Citadel Advisors LLC (4)                              |                                 | 1,263,101                           |   | 5.68% |   | - |   | - |   | 4.54% |
|         | Magnetar Financial LLC (5)                            |                                 | 1,250,000                           |   | 5.62% |   | - |   | - |   | 4.49% |
|         | RJ Healthcare SPAC, LLC (our sponsor) (6)             |                                 | -                                   |   | - |   | 5,447,500 |   | 97.93% |   | 19.59% |
|         | John Ellis Bush (6)                                   |                                 | -                                   |   | - |   | 5,447,500 |   | 97.93% |   | 19.59% |
|         | Richard L. Jackson (6)                                |                                 | -                                   |   | - |   | 5,447,500 |   | 97.93% |   | 19.59% |
|         | Douglas B. Kline                                      |                                 | -                                   |   | - |   | 15,000 |   | * |   | * |
|         | David A. Perdue, Jr.                                  |                                 | -                                   |   | - |   | 50,000 |   | * |   | * |
|         | Marilyn B. Tavenner                                   |                                 | -                                   |   | - |   | 25,000 |   | * |   | * |
|         | Carlos A. Migoya                                      |                                 | -                                   |   | - |   | 25,000 |   | * |   | * |
|         | All directors and officers as a group (6 individuals) |                                 | -                                   |   | - |   | 5,562,500 |   | 100% |   | 20% |

----

| * | Less than one percent. |
|---|------------------------|
|  | 1) | Based on 22,250,000 shares of Class A Common Stock outstanding. |
|--|----|-----------------------------------------------------------------|
|  | 2) | Based on 5,562,500 shares of Class B Common Stock outstanding. Interests shown consist solely of founder shares, which will automatically convert into Class A Common Stock at the time of our initial business combination. |
|--|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | 3) | Based on 27,812,500 shares of common stock outstanding, which includes 22,250,000 shares of Class A Common Stock and 5,562,500 shares of Class B Common Stock. |
|--|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | 4) | Based on a Schedule 13G/A filed on February 14, 2022, which reported ownership as of December 31, 2021, by Citadel Advisors LLC (“Citadel Advisors”), Citadel Advisors Holdings LP (“CAH”), Citadel GP LLC (“CGP”), Citadel Securities LLC                  (“Citadel Securities”), Citadel Securities Group LP (“CALC4”), Citadel Securities GP LLC (“CSGP”) and Mr. Kenneth Griffin (“Mr. Griffin”). Citadel Advisors, CAH and CGP share voting and dispositive power over 1,250,000 of the reported                  shares. Citadel Securities, CALC4 and CSGP share voting and dispositive power over 13,101of the reported shares.  Mr. Griffin shares voting and dispositive power over the reported shares. The address of the principal business office of                  each of the reporting persons is 131 S. Dearborn Street, 32nd Floor, Chicago, Illinois 60603. |
|--|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | 5) | Based on a Schedule 13G/A filed on February 4, 2022, which reported ownership as of December 31, 2021, by Magnetar Financial LLC (“Magnetar Financial”), Magnetar Capital Partners LP (Magnetar Capital Partners”), Supernova Management LLC              (“Supernova Management”), and Alec N. Litowitz (“Mr. Litowitz”).  Magnetar Financial, Magnetar Capital Partners, Supernova Management, and Mr. Litowitz share voting and dispositive power over the reported shares. The address of the principal              business office for each of the reporting persons is 1603 Orrington Avenue, 13th Floor, Evanston, Illinois 60201. |
|--|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | 6) | Based on a Schedule 13G filed on February 11, 2022.  RJ Healthcare SPAC, LLC, the Company’s sponsor, is the record holder of the reported shares.  Entities controlled by Richard L. Jackson and John Ellis Bush, respectively, are members of              the sponsor and Messrs. Jackson and Bush serve as managers of the sponsor, but Mr. Jackson has two of the three votes on the board of managers and thus holds the ultimate voting and investment control over the shares held by the sponsor. Each              of Mr. Jackson and Mr. Bush disclaims beneficial ownership over any securities held by the sponsor in which he does not have any pecuniary interest. |
|--|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| ITEM 13. | CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE |
|----------|---------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|  | • | repayment of an aggregate of up to $300,000 in loans made to us by our sponsor to cover offering- related and organizational expenses; |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------|
|  | • | payment to an affiliate of our sponsor of a total of $10,000 per month for office space, administrative and support services; |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------|
|  | • | reimbursement for any out-of-pocket expenses related to identifying, investigating and completing an initial business combination; and |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------|
|  | • | repayment of loans which may be made by our sponsor or an affiliate of our sponsor or certain of our directors and officers to fund working capital or finance transaction costs in connection with an intended initial business combination,              the terms of which have not been determined nor have any written agreements been executed with respect thereto. Up to $1,500,000 of such loans may be convertible into warrants, at a price of $1.00 per warrant at the option of the lender. |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| ITEM 14. | PRINCIPAL ACCOUNTANT FEES AND SERVICES |
|----------|----------------------------------------|
| (in thousands)     |   | Year Ended December 31, 2021 |    |
|--------------------|--------|------------------------------|---------|
| Audit Fees         |   | $                            | 123,548 |   |
| Audit-Related Fees |   |                         | -       |   |
| Tax Fees           |   |                         | -       |   |
| All Other Fees     |   |                         | -       |   |
| Total              |   | $                            | 123,548 |   |

----

Table of Contents

| ITEM 15. | EXHIBITS AND FINANCIAL STATEMENT SCHEDULES |
|----------|--------------------------------------------|

| (a) | (1) | Financial Statements: See Index to Consolidated Financial Statements on page F‐1 of this Annual Report. |
|-----|-----|---------------------------------------------------------------------------------------------------------------|

|   | (2) | Exhibits: The exhibits listed on the Exhibit Index set forth immediately following Item 16 are filed or furnished as part of this Annual Report. The Exhibit Index is incorporated herein by reference. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ITEM 16. | FORM 10‐K SUMMARY |
|----------|-------------------------|
|          |   |                                                                                                                                       |   | Incorporated by Reference |   |             |
|---------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------|--------|-------------|
| ExhibitNumber |   | Description of Exhibit                                                                                                                     |   | Form                      |   | File Number |   | Date ofFiling |   | ExhibitNumber |   | Filed* or Furnished**Herewith |
| 3.1           |   | Amended and Restated Certificate of Incorporation of the Company                                                                           |   | 8-K                       |   | 001-41128   |   | December 14, 2021 |   | 3.1 |   |   |
|          |   |                                                                                                                                       |   |                      |   |        |   |   |   |   |   |   |
| 3.2           |   | Amended and Restated Bylaws of the Company                                                                                                 |   | S-1/A                     |   | 333-254727  |   | May 12, 2021 |   | 3.4 |   |   |
|          |   |                                                                                                                                       |   |                      |   |        |   |   |   |   |   |   |
| 4.1           |   | Specimen Unit Certificate                                                                                                                  |   | S-1/A                     |   | 333-254727  |   | November 22, 2021 |   | 4.1 |   |   |
|          |   |                                                                                                                                       |   |                      |   |        |   |   |   |   |   |   |
| 4.2           |   | Specimen Class A Common Stock Certificate                                                                                                  |   | S-1/A                     |   | 333-254727  |   | November 22, 2021 |   | 4.2 |   |   |
|          |   |                                                                                                                                       |   |                      |   |        |   |   |   |   |   |   |
| 4.3           |   | Specimen Warrant Certificate (included in Exhibit 4.4)                                                                                     |   | 8-K                       |   | 001-41128   |   | December 14, 2021 |   | 4.1 |   |   |
|          |   |                                                                                                                                       |   |                      |   |        |   |   |   |   |   |   |
| 4.4           |   | Warrant Agreement, dated December 8, 2021, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent |   | 8-K                       |   | 001-41128   |   | December 14, 2021 |   | 4.1 |   |   |
|          |   |                                                                                                                                       |   |                      |   |        |   |   |   |   |   |   |
| 4.5           |   | Description of Securities                                                                                                                  |   |                      |   |        |   |   |   |   |   | * |
|          |   |                                                                                                                                       |   |                      |   |        |   |   |   |   |   |   |
| 10.1          |   | Promissory Note, dated March 8, 2021, issued to RJ Healthcare SPAC, LLC                                                                    |   | S-1                       |   | 333-254727  |   | March 25, 2021 |   | 10.1 |   |   |
|          |   |                                                                                                                                       |   |                      |   |        |   |   |   |   |   |   |
| 10.2          |   | Letter Agreement, dated December 8, 2021, by and among the Company, its officers and directors, and RJ Healthcare SPAC, LLC                |   | 8-K                       |   | 001-41128   |   | December 14, 2021 |   | 10.1 |   |   |

----

Table of Contents

| 10.3   |   | Investment Management Trust Agreement, dated December 8, by and between the Company and Continental Stock Transfer & Trust Company, as trustee            |   | 8-K    |   | 001-41128  |   | December 14, 2021 |   | 10.2   |   |   |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|--------|------------|--------|-------------------|--------|--------|--------|--------|
|   |   |                                                                                                                                                          |   |   |   |       |   |              |   |   |   |   |
| 10.4   |   | Registration Rights Agreement, dated December 8, 2021, by and among the Company and certain security holders                                                  |   | 8-K    |   | 001-41128  |   | December 14, 2021 |   | 10.3   |   |   |
|   |   |                                                                                                                                                          |   |   |   |       |   |              |   |   |   |   |
| 10.5   |   | Administrative Services Agreement, dated December 8, 2021, by and between the Company and RJ Healthcare SPAC, LLC                                             |   | 8-K    |   | 001-41128  |   | December 14, 2021 |   | 10.4   |   |   |
|   |   |                                                                                                                                                          |   |   |   |       |   |              |   |   |   |   |
| 10.6   |   | Sponsor Warrants Purchase Agreement, dated December 8, 2021, by and between the Company and RJ Healthcare SPAC, LLC                                           |   | 8-K    |   | 001-41128  |   | December 14, 2021 |   | 10.5   |   |   |
|   |   |                                                                                                                                                          |   |   |   |       |   |              |   |   |   |   |
| 10.7   |   | Securities Subscription Agreement, dated March 8, 2021, by and between the Company and RJ Healthcare SPAC, LLC                                                |   | S-1    |   | 333-254727 |   | March 25, 2021    |   | 10.5   |   |   |
|   |   |                                                                                                                                                          |   |   |   |       |   |              |   |   |   |   |
| 10.8   |   | Surrender of Shares and Amendment No. 1 to Securities Subscription Agreement, dated November 22, 2021, by and between the Company and RJ Healthcare SPAC, LLC |   | S-1/A  |   | 333-254727 |   | November 22, 2021 |   | 10.9   |   |   |
|   |   |                                                                                                                                                          |   |   |   |       |   |              |   |   |   |   |
| 10.9   |   | Indemnity Agreement, dated December 8, 2021, by and between the Company and John Ellis “Jeb” Bush                                                 |   | 8-K    |   | 001-41128  |   | December 14, 2021 |   | 10.6   |   |   |
|   |   |                                                                                                                                                          |   |   |   |       |   |              |   |   |   |   |
| 10.10  |   | Indemnity Agreement, dated December 8, 2021, by and between the Company and Richard L. Jackson                                                                |   | 8-K    |   | 001-41128  |   | December 14, 2021 |   | 10.7   |   |   |
|   |   |                                                                                                                                                          |   |   |   |       |   |              |   |   |   |   |
| 10.11  |   | Indemnity Agreement, dated December 8, 2021, by and between the Company and Douglas B. Kline                                                                  |   | 8-K    |   | 001-41128  |   | December 14, 2021 |   | 10.8   |   |   |
|   |   |                                                                                                                                                          |   |   |   |       |   |              |   |   |   |   |
| 10.12  |   | Indemnity Agreement, dated December 8, 2021, by and between the Company and David A. Perdue, Jr.                                                              |   | 8-K    |   | 001-41128  |   | December 14, 2021 |   | 10.9   |   |   |
|   |   |                                                                                                                                                          |   |   |   |       |   |              |   |   |   |   |
| 10.13  |   | Indemnity Agreement, dated December 8, 2021, by and between the Company and Marilyn B. Tavenner                                                               |   | 8-K    |   | 001-41128  |   | December 14, 2021 |   | 10.10  |   |   |

----

Table of Contents

| 10.14  |   | Indemnity Agreement, dated December 8, 2021, by and between the Company and Carlos A. Migoya                 |   | 8-K    |   | 001-41128  |   | December 14, 2021 |   | 10.13  |   |   |
|--------|--------|--------------------------------------------------------------------------------------------------------------|--------|--------|--------|------------|--------|-------------------|--------|--------|--------|--------|
|   |   |                                                                                                         |   |   |   |       |   |              |   |   |   |   |
| 14.1   |   | Code of Business Conduct and Ethics                                                                          |   | S-1/A  |   | 333-254727 |   | May 13, 2021      |   | 14     |   |   |
|   |   |                                                                                                         |   |   |   |       |   |              |   |   |   |   |
| 31.1   |   | Certification of the Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a)                    |   |   |   |       |   |              |   |   |   | *      |
|   |   |                                                                                                         |   |   |   |       |   |              |   |   |   |   |
| 31.2   |   | Certification of the Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a)                    |   |   |   |       |   |              |   |   |   | *      |
|   |   |                                                                                                         |   |   |   |       |   |              |   |   |   |   |
| 32.1   |   | Certification of the Chief Executive Officer required by Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. 1350 |   |   |   |       |   |              |   |   |   | **     |
|   |   |                                                                                                         |   |   |   |       |   |              |   |   |   |   |
| 32.2   |   | Certification of the Chief Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. 1350 |   |   |   |       |   |              |   |   |   | **     |

----

Table of Contents

|                 | JACKSON ACQUISITION COMPANY |
|----------------------|-----------------------------|
| Date: March 25, 2022 |                        |   |
|                 |                        |   |
|                 | By:                         | /s/ RICHARD L. JACKSON |
|                 |                        | Richard L. Jackson |
|                 |                        | Chief Executive Officer |
| Signature                |   | Title                                        |   | Date           |
|--------------------------|--------|----------------------------------------------|--------|----------------|
|                     |   |                                         |   |           |
| /s/ RICHARD L. JACKSON   |   | President and Chief Executive Officer        |   | March 25, 2022 |
| Richard L. Jackson       |   | (Principal Executive Officer)                |   |           |
|                     |   |                                         |   |           |
| /s/ DOUGLAS B. KLINE     |   | Chief Financial Officer and Treasurer        |   | March 25, 2022 |
| Douglas B. Kline         |   | (Principal Financial and Accounting Officer) |   |           |
|                     |   |                                         |   |           |
| /s/ JOHN ELLIS BUSH      |   | Chairman of the Board                        |   | March 25, 2022 |
| John Ellis Bush          |   |                                         |   |           |
|                     |   |                                         |   |           |
| /s/ CARLOS A. MIGOYA     |   | Director                                     |   | March 25, 2022 |
| Carlos A. Migoya         |   |                                         |   |           |
|                     |   |                                         |   |           |
| /s/ DAVID A. PERDUE, JR. |   | Director                                     |   | March 25, 2022 |
| David A. Perdue, Jr.     |   |                                         |   |           |
|                     |   |                                         |   |           |
| /s/ MARILYN B. TAVENNER  |   | Director                                     |   | March 25, 2022 |
| Marilyn B. Tavenner      |   |                                         |   |           |

----

Table of Contents

| Report of Marcum LLP, Independent Registered Public Accounting Firm (PCAOB ID 688) | F-2                                                                                                                    |
|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|
| Financial Statements:                                                              |                                                                                                                   |
|                                                                               | Balance sheet as of December 31, 2021                                                                                  | F-3 |
|                                                                               | Statements of operations for the period March 5, 2021 (inception) through December 31, 2021                            | F-4 |
|                                                                               | Statements of changes in stockholders’ equity for the period March 5, 2021 (inception) through December 31, 2021 | F-5 |
|                                                                               | Statements of cash flows for the period March 5, 2021 (inception) through December 31, 2021                            | F-6 |
|                                                                               | Notes to the financial statements                                                                                      | F-7 |

----

Table of Contents

----

Table of Contents

| ASSETS                                                                                                                                                               |   |   |        |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|-------------|
| Current Assets:                                                                                                                                                      |   |   |        |
| Cash                                                                                                                                                                 |   | $      | 1,923,321   |   |
| Prepaid expenses                                                                                                                                                     |   |   | 15,350      |   |
| Other current assets                                                                                                                                                 |   |   | 380,000     |   |
| Total Current Assets                                                                                                                                                 |   |   | 2,318,671   |   |
|                                                                                                                                                                 |   |   |        |   |
| Investments held in Trust Account                                                                                                                                    |   |   | 203,000,654 |   |
|                                                                                                                                                                 |   |   |        |   |
| Other assets                                                                                                                                                         |   |   | 355,015     |   |
| Total Assets                                                                                                                                                         |   | $      | 205,674,340 |   |
|                                                                                                                                                                 |   |   |        |   |
| LIABILITIES, COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS’ DEFICIT                                                                             |   |   |        |   |
| Accounts payable and accrued expenses                                                                                                                                |   | $      | 1,091,191   |   |
| Accrued offering costs                                                                                                                                               |   |   | 410,768     |   |
| Overallotment liability                                                                                                                                              |   |   | 325,831     |   |
| Total Current Liabilities                                                                                                                                            |   |   | 1,827,790   |   |
|                                                                                                                                                                 |   |   |        |   |
| Derivative warrant liabilities                                                                                                                                       |   |   | 9,584,400   |   |
| Deferred underwriting commission                                                                                                                                     |   |   | 7,000,000   |   |
|                                                                                                                                                                 |   |   |        |   |
| Total Liabilities                                                                                                                                                    |   |   | 18,412,190  |   |
|                                                                                                                                                                 |   |   |        |   |
| COMMITMENTS AND CONTINGENCIES (Note 6)                                                                                                                               |   |   |        |   |
|                                                                                                                                                                 |   |   |        |   |
| Class A common stock subject to possible redemption; 20,000,000 shares (at redemption value of $10.15 per share)                                                     |   |   | 203,000,000 |   |
|                                                                                                                                                                 |   |   |        |   |
| Stockholders' deficit:                                                                                                                                               |   |   |        |   |
| Preferred Stock, $0.0001 par value; 5,000,000 shares authorized; none issued and Outstanding                                                                         |   |   | —     |   |
| Class A common stock, $0.0001 par value, 500,000,000 shares authorized, 0 shares issued and outstanding (excluding 20,000,000 shares subject to possible redemption) |   |   | —     |   |
| Class B common stock, $0.0001 par value, 50,000,000 shares authorized, 5,750,000 shares issued and outstanding (1)                                                   |   |   | 575         |   |
| Additional paid-in capital                                                                                                                                           |   |   | —     |   |
| Accumulated deficit                                                                                                                                                  |   |   | (15,738,425 | ) |
| Total Stockholders’ Deficit                                                                                                                                    |   |   | (15,737,850 | ) |
| Total Liabilities, Common Stock Subject to Possible Redemption and Stockholders’ Deficit                                                                       |   | $      | 205,674,340 |   |
| (1) | Includes an aggregate of up to 750,000 shares of Class B ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters (see Note 7 and Note 11). |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|                                                                                         |   |                                                             |       |
|----------------------------------------------------------------------------------------------|--------|------------------------------------------------------------------|------------|
|                                                                                         |   | For the PeriodMarch 5, 2021 (Inception)Through December 31, 2021 |       |
| REVENUE                                                                                      |   | $                                                                | —    |   |
|                                                                                         |   |                                                             |       |   |
| EXPENSES                                                                                     |   |                                                             |       |   |
| Administration fee - related party                                                           |   |                                                             | 5,806      |   |
| General and administrative                                                                   |   |                                                             | 377,338    |   |
| TOTAL EXPENSES                                                                               |   |                                                             | 383,144    |   |
|                                                                                         |   |                                                             |       |   |
| OTHER INCOME (EXPENSES)                                                                      |   |                                                             |       |   |
| Investment income earned on investment held in Trust Account                                 |   |                                                             | 654        |   |
| Transaction costs allocable to warrant liability                                             |   |                                                             | (836,603   | ) |
| Excess fair value of private warrants over proceeds                                          |   |                                                             | (3,059,200 | ) |
| Change in fair value of over-allotment liability                                             |   |                                                             | 94,929     |   |
| Change in fair value of derivative warrants                                                  |   |                                                             | 16,234,800 |   |
| TOTAL OTHER INCOME (EXPENSES)                                                                |   |                                                             | 12,434,580 |   |
|                                                                                         |   |                                                             |       |   |
| Net income attributable to common stock                                                      |   | $                                                                | 12,051,436 |   |
|                                                                                         |   |                                                             |       |   |
| Weighted average number of shares of Class A common stock outstanding, basic and diluted (1) |   |                                                             | 1,196,013  |   |
| Basic and diluted net income per share of Class A common stock                               |   | $                                                                | 1.95       |   |
|                                                                                         |   |                                                             |       |   |
| Weighted average number of shares of Class B common stock outstanding, basic and diluted     |   |                                                             | 5,000,000  |   |
| Basic and diluted net income per share of Class B common stock                               |   | $                                                                | 1.95       |   |
| (1) | Excludes an aggregate of up to 750,000 shares of Class B ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters (see Note 7 and Note 11). |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|                                                           |        | Class BCommon Stock |           |   | AdditionalPaid-InCapital |   |         |                AccumulatedDeficit |        |        |                Stockholders’Deficit |        |
|-----------------------------------------------------------|--------|---------------------|-----------|--------|--------------------------|--------|---------|----------------------------------------|--------|--------|------------------------------------------------|--------|
||
|                                                      |   | Shares              |      |   | Amount                   |   |
| Balance as of March 5, 2021 (inception)                   |   |                | —   |   |                     | $      | — |                                   |   | $      | —                                        |   |   | $ | — |   |   | $ | — |   |
|                                                      |   |                |      |   |                     |   |    |                                   |   |   |                                           |   |   |   |   |   |   |   |   |   |
| Issuance of Class B common stock to Sponsor (1)           |   |                | 5,750,000 |   |                     |   | 575     |                                   |   |   | 24,425                                         |   |   |   | — |   |   |   | 25,000 |   |
|                                                      |   |                |      |   |                     |   |    |                                   |   |   |                                           |   |   |   |   |   |   |   |   |   |
| Remeasurement of Class A common stock to redemption value |   |                | —   |   |                     |   | — |                                   |   |   | (24,425                                        | )      |   |   | (27,789,861 | ) |   |   | (27,814,286 | ) |
|                                                      |   |                |      |   |                     |   |    |                                   |   |   |                                           |   |   |   |   |   |   |   |   |   |
| Net income                                                |   |                | —   |   |                     |   | — |                                   |   |   | —                                        |   |   |   | 12,051,435 |   |   |   | 12,051,435 |   |
| Balance as of December 31, 2021                           |   |                | 5,750,000 |   |                     | $      | 575     |                                   |   | $      | —                                        |   |   | $ | (15,738,425 | ) |   | $ | (15,737,850 | ) |
| (1) | Includes an aggregate of up to 750,000 shares of Class B ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters (see Note 7 and Note 11). |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|                                                                          |   | For the period March 5, 2021 (Inception) Through December 31, 2021 |         |
|-------------------------------------------------------------------------------|--------|--------------------------------------------------------------------|--------------|
| Cash Flows From Operating Activities:                                         |   |                                                               |         |
| Net income                                                                    |   | $                                                                  | 12,051,436   |   |
| Adjustments to reconcile net income to net cash used in operating activities: |   |                                                               |         |   |
| Investment income earned on investment held in Trust Account                  |   |                                                               | (654         | ) |
| Change in fair value of derivative liabilities                                |   |                                                               | (16,234,800  | ) |
| Change in fair value of overallotment liability                               |   |                                                               | (94,929      | ) |
| Transaction costs allocable to warrant liability                              |   |                                                               | 836,603      |   |
| Excess fair value of private warrants over proceeds                           |   |                                                               | 3,059,200    |   |
| Changes in operating assets and liabilities:                                  |   |                                                               |         |   |
| Prepaid expenses                                                              |   |                                                               | (15,350      | ) |
| Other current assets                                                          |   |                                                               | (380,000     | ) |
| Other assets                                                                  |   |                                                               | (355,015     | ) |
| Accounts payable and accrued expenses                                         |   |                                                               | 1,091,191    |   |
| Net Cash Used In Operating Activities                                         |   |                                                               | (42,318      | ) |
|                                                                          |   |                                                               |         |   |
| Cash Flows From Investing Activities:                                         |   |                                                               |         |   |
| Cash deposited into Trust Account                                             |   |                                                               | (203,000,000 | ) |
| Net Cash Used In Investing Activities                                         |   |                                                               | (203,000,000 | ) |
|                                                                          |   |                                                               |         |   |
| Cash Flows From Financing Activities:                                         |   |                                                               |         |   |
| Proceeds from sale of Units in Public Offering, net of underwriting fee       |   |                                                               | 196,000,000  |   |
| Proceeds from sale of Private Placement Warrants                              |   |                                                               | 9,560,000    |   |
| Proceeds from note payable                                                    |   |                                                               | 300,000      |   |
| Repayment of note payable                                                     |   |                                                               | (300,000     | ) |
| Proceeds from issuance of Class B common stock to sponsor                     |   |                                                               | 25,000       |   |
| Payment of offering costs                                                     |   |                                                               | (619,361     | ) |
| Net Cash Provided By Financing Activities                                     |   |                                                               | 204,965,639  |   |
|                                                                          |   |                                                               |         |   |
| Net change in cash                                                            |   |                                                               | 1,923,321    |   |
| Cash at beginning of period                                                   |   |                                                               | —      |   |
| Cash at end of period                                                         |   | $                                                                  | 1,923,321    |   |
|                                                                          |   |                                                               |         |   |
| Supplemental disclosure of non-cash financing activities:                     |   |                                                               |         |   |
| Deferred underwriters’ commissions                                      |   | $                                                                  | 7,000,000    |   |
| Initial classification of fair value of Public warrants                       |   | $                                                                  | 13,200,000   |   |
| Fair value of overallotment liability                                         |   | $                                                                  | 420,760      |   |
| Deferred offering costs included in accrued offering costs                    |   | $                                                                  | 410,768      |   |
| Initial classification of common stock subject to redemption                  |   | $                                                                  | 175,185,714  |   |

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

| Gross proceeds                                      |   | $      | 200,000,000 |   |
|-----------------------------------------------------|--------|--------|-------------|--------|
| Less:                                               |   |   |        |   |
| Transaction costs allocated to Class A common stock |   |   | (11,193,526 | )      |
| Overallotment liability                             |   |   | (420,760    | )      |
| Proceeds allocated to Public Warrants               |   |   | (13,200,000 | )      |
|                                                |   |   | (24,815,286 | )      |
|                                                |   |   |        |   |
| Plus:                                               |   |   |        |   |
| Remeasurement of carrying value to redemption value |   |   | 27,814,286  |   |
| Class A common stock subject to possible redemption |   | $      | 203,000,000 |   |
|                                                   |   | For the Period from March 5, 2021 (inception) throughDecember 31, 2021 |      |
|--------------------------------------------------------|--------|------------------------------------------------------------------------|-----------|
|                                                   |   | Class A                                                                |      |   | Class B |   |
| Basic and diluted net income per share of common stock |   |                                                                   |      |   |   |   |
| Numerator:                                             |   |                                                                   |      |   |   |   |
| Allocation of net income, as adjusted                  |   | $                                                                      | 2,326,283 |   |   | $ | 9,725,153 |   |
| Denominator:                                           |   |                                                                   |      |   |   |   |   |   |
| Basic and diluted weighted average shares outstanding  |   |                                                                   | 1,196,013 |   |   |   | 5,000,000 |   |
|                                                   |   |                                                                   |      |   |   |   |   |   |
| Basic and diluted net income per share of common stock |   | $                                                                      | 1.95      |   |   | $ | 1.95 |   |

----

Table of Contents

| • | Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; |
|---------|-----------------------------------------------------------------------------------------------------------------------|
| • | Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for                identical or similar instruments in markets that are not active; and |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which                one or more significant inputs or significant value drivers are unobservable. |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

| • | in whole and not in part; |
|---------|---------------------------|
| • | at a price of $0.01 per Public Warrant; |
|---------|-----------------------------------------|
| • | upon a minimum of 30 days’ prior written notice of redemption, or the 30-day redemption period to each warrant holder; and |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| • | if, and only if, the last reported sale price of the Class A common stock for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which                the Company sends the notice of redemption to warrant holders (the “Reference Value”) equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reverse stock splits, consolidations, reorganizations,                recapitalizations and other similar transactions). |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | in whole and not in part; |
|---------|---------------------------|
| • | at a price of $0.10 per warrant provided that the holder will be able to exercise their warrants on cashless basis prior to redemption and receive a specified number of shares based on                the redemption date and the fair market value of the Class A common stock; |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | upon a minimum of 30 days’ prior written notice of redemption; |
|---------|----------------------------------------------------------------------|
| • | if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted for stock splits, stock dividends, reverse stock splits, rights issuances, consolidations,                reorganizations, recapitalizations and other similar transactions); and |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| • | if, and only if, the Reference Value is less than $18.00 per share (as adjusted for stock splits, stock dividends, reverse stock splits, consolidations, reorganizations, recapitalizations                and other similar transactions), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above. |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Description                                          |   | Level  |   |   | December 31, 2021 |   |
|------------------------------------------------------|--------|--------|--------|--------|-------------------|--------|
| Liabilities:                                         |   |   |   |   |              |   |
| Overallotment Option                                 |   |   | 3      |   |              | $      | 325,831 |   |
| Warrant liability – Private Placement Warrants |   |   | 3      |   |              |   | 4,684,400 |   |
| Warrant liability – Public Warrants            |   |   | 3      |   |              |   | 4,900,000 |   |
|                                                 |   |   |   |   |              | $      | 9,910,231 |   |

----

Table of Contents

|                                     |   | December 13, 2021 |   |   |   | December 31, 2021 |   |   |
|------------------------------------------|--------|-------------------|--------|--------|--------|-------------------|--------|--------|
| Stock price                              |   | $                 | 9.34   |   |   |              | $      | 9.72   |   |   |
| Exercise price                           |   | $                 | 11.50  |   |   |              | $      | 11.50  |   |   |
| Risk-free interest rate                  |   |              | 1.21   |   | %      |              |   | 1.26   |   | % |
| Expected life of warrants                |   |              | 6.75   |   | years  |              |   | 6.70   |   | years |
| Expected volatility of underlying shares |   |              | 24.7   |   | %      |              |   | 10.0   |   | % |
| Dividend yield                           |   |              | 0      |   | %      |              |   | 0      |   | % |
| Probability of business combination      |   |              | 90     |   | %      |              |   | 90     |   | % |
|                                     |   | December 13, 2021 |   |   |   | December 31, 2021 |   |   |
|------------------------------------------|--------|-------------------|--------|--------|--------|-------------------|--------|--------|
| Risk-free interest rate                  |   |              | 0.03   |   | %      |              |   | 0.03   |   | % |
| Expected life of warrants                |   |              | 0.12   |   | years  |              |   | 0.07   |   | years |
| Expected volatility of underlying shares |   |              | 10.0   |   | %      |              |   | 10.0   |   | % |
| Dividend yield                           |   |              | 0      |   | %      |              |   | 0      |   | % |
|                                     |   | Private PlacementWarrants |       |   | PublicWarrants |   |       | Warrant Liabilities |   |   | OverallotmentLiability |   |
|------------------------------------------|--------|---------------------------|------------|--------|----------------|--------|------------|---------------------|--------|--------|------------------------|--------|
| Fair value at March 5, 2021 (inception)  |   | $                         | —    |   |           | $      | —    |                |   | $      | —                |   |   | $ | — |   |
| Initial measurement at December 13, 2021 |   |                      | 12,619,200 |   |           |   | 13,200,000 |                |   |   | 25,819,200             |   |   |   | 420,760 |   |
| Change in fair value                     |   |                      | (7,934,800 | )      |           |   | (8,300,000 | )                   |   |   | (16,234,800            | )      |   |   | (94,929 | ) |
| Fair value at December 31, 2021          |   | $                         | 4,684,400  |   |           | $      | 4,900,000  |                |   | $      | 9,584,400              |   |   | $ | 325,831 |   |

----

Table of Contents

|                                 |   | December 31,2021 |    |
|--------------------------------------|--------|------------------|---------|
| Deferred tax asset                   |   |             |    |
| Net operating loss                   |   | $                | 34,498  |   |
| Startup/organizational costs         |   |             | 45,825  |   |
| Total deferred tax asset             |   |             | 80,323  |   |
| Valuation Allowance                  |   |             | (80,323 | ) |
| Deferred tax asset, net of allowance |   | $                | -       |   |
|                          |   | Period EndedDecember 31,2021 |    |
|-------------------------------|--------|------------------------------|---------|
| Federal                       |   |                         |    |
| Current                       |   | $                            | -       |   |
| Deferred                      |   |                         | (80,323 | ) |
| State and Local               |   |                         |    |   |
| Current                       |   |                         | -       |   |
| Deferred                      |   |                         | -       |   |
| Change in valuation allowance |   |                         | 80,323  |  |
| Income tax provision          |   | $                            | -       |   |

----

Table of Contents

|                                             |   | Period EndedDecember 31,2021 |   |
|--------------------------------------------------|--------|------------------------------|--------|
| Statutory federal income tax rate                |   |                         | 21.0   | % |
| State taxes, net of federal tax benefit          |   |                         | 0.00   | % |
| Change in fair value of warrant liability        |   |                         | (22.96 | )% |
| Change in fair value of overallotment liability  |   |                         | (0.17  | )% |
| Transaction costs allocable to warrant liability |   |                         | 1.46   | % |
| Change in valuation allowance                    |   |                         | 0.67   | % |
| Income tax provision (benefit)                   |   |                         | 0.00   | % |

----